Absci Corporation - Common Stock (ABSI)
4.7100
+0.3600 (8.28%)
Absci Corp is a biotechnology company that focuses on advancing the development of protein-based therapeutics through its innovative AI-driven platform
The company combines synthetic biology with machine learning to enhance the discovery, design, and production of complex proteins and antibodies. Absci’s technology aims to revolutionize the way biologic drugs are developed, enabling faster and more efficient creation of new drug candidates to address unmet medical needs in various therapeutic areas. By leveraging its proprietary platform, Absci aims to support pharmaceutical and biotech partners in bringing next-generation therapies to market.
Previous Close | 4.350 |
---|---|
Open | 4.300 |
Bid | 4.710 |
Ask | 4.720 |
Day's Range | 4.300 - 4.880 |
52 Week Range | 2.450 - 6.720 |
Volume | 8,492,717 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 8,090,449 |
News & Press Releases
![](https://cdn.benzinga.com/files/images/story/2025/01/22/abbott-shutter.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/22/ABSI.png?width=1200&height=800&fit=crop)
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.
Via Benzinga · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/22/Procter--Gamble-pg-shutter.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/22/Seagate-Barracuda-1tb.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Via Benzinga · January 17, 2025
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.
By Absci Corporation · Via GlobeNewswire · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/22/Analysts.png?width=1200&height=800&fit=crop)
Via Benzinga · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/22/Cathie-Wood-Takes-Profit-On-Hot-AI-Stock.jpeg?width=1200&height=800&fit=crop)
Cathie Wood-led Ark Invest made significant trades involving ACCD, DE, NTLA, PATH, CCJ, OKLO, ILMN, ESLT, and ABSI.
Via Benzinga · January 22, 2025
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics
By Absci Corporation; Owkin · Via GlobeNewswire · January 10, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 8, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/08/AAR-Corp-.png?width=1200&height=800&fit=crop)
Via Benzinga · January 8, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/08/Businessmen-Making-Handshake-With-Partne.jpeg?width=1200&height=800&fit=crop)
Absci shares are rising after announcing a strategic collaboration with Advanced Micro Devices Inc. The partnership will enhance Absci's AI drug discovery capabilities using AMD Instinct accelerators and ROCm software.
Via Benzinga · January 8, 2025
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software
By Absci Corporation · Via GlobeNewswire · January 8, 2025
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications
By Absci Corporation; Invetx · Via GlobeNewswire · January 6, 2025
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
By Absci Corporation · Via GlobeNewswire · January 2, 2025
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development for androgenic alopecia
By Absci Corporation · Via GlobeNewswire · December 12, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/12/Palantir--Salesforce--Okta--Meta--And-Te.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 12, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/10/United-Natural-Foods-Inc-.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 10, 2024
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36th Annual Piper Sandler Healthcare Conference in New York, NY.
By Absci Corporation · Via GlobeNewswire · November 21, 2024
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration
By Absci Corporation · Via GlobeNewswire · November 12, 2024
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City.
By Absci Corporation · Via GlobeNewswire · November 7, 2024
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody
By Absci Corporation · Via GlobeNewswire · October 31, 2024
![](https://ml.globenewswire.com/media/8a7eb744-ee7b-4c4b-89cf-387103eed7ab/small/absci-namelogo-png.png)
VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
By Absci Corporation · Via GlobeNewswire · October 24, 2024